Marc Robillard
Co-Founder & Chief Scientific Officer Tagworks Pharmaceuticals
Seminars
Wednesday 10th March 2027
Discovery & Development of Click-To-Release ADCs With Enhanced Therapeutic Potential
- Using the learnings from our first-in-class clinical-stage click-cleavable ADC, TGW101, targeting TAG72, to inform next-generation designs and further expand the ADC target universe into the non-internalising target space
- Highlighting how the Click-to-Release linker system delivers a highly differentiated safety and efficacy profile across multiple payload classes
- Discussing protein design considerations and the functional characterisation of our discovery-phase ADCs
